These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34124183)

  • 1. Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis.
    Yoshida A; Matsuoka K; Ueno F; Morizane T; Endo Y; Hibi T
    Inflamm Intest Dis; 2021 May; 6(2):117-122. PubMed ID: 34124183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis.
    Aoyama Y; Inaba T; Takahashi S; Yasuhara H; Hiraoka S; Morimoto T; Colvin HS; Wato M; Ando M; Nakamura S; Mizobuchi K; Okada H
    BMC Gastroenterol; 2021 Aug; 21(1):325. PubMed ID: 34425765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.
    Burke KE; Khalili H; Garber JJ; Haritunians T; McGovern DPB; Xavier RJ; Ananthakrishnan AN
    Inflamm Bowel Dis; 2018 Jul; 24(8):1840-1848. PubMed ID: 29718226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
    Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
    Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.
    Lee SH; Walshe M; Oh EH; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Greener T; Weizman AV; Silverberg MS; Ye BD
    Inflamm Bowel Dis; 2021 Aug; 27(9):1452-1461. PubMed ID: 33269403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Proteinase 3 Antineutrophil Cytoplasmic Antibody-Associated Ulcerative Colitis Presenting as Recurrent Intestinal Pseudo-Obstruction in a Teenage Patient With
    Yang CW; Kao YC; Lin PC; Chien HY; Lin SC; Lee YH; Huang YL; Fang SB
    Front Pediatr; 2022; 10():822491. PubMed ID: 35281249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring.
    Kumar P; Vuyyuru SK; Das P; Kante B; Ranjan MK; Thomas DM; Mundhra S; Sahu P; Venigalla PM; Jain S; Goyal S; Golla R; Virmani S; Singh MK; Sachdeva K; Sharma R; Dash NR; Makharia G; Kedia S; Ahuja V
    Intest Res; 2023 Oct; 21(4):460-470. PubMed ID: 36926698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease.
    Horn MP; Peter AM; Righini Grunder F; Leichtle AB; Spalinger J; Schibli S; Sokollik C
    PLoS One; 2018; 13(12):e0208974. PubMed ID: 30557305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease.
    Xu Y; Xu F; Li W; Li M; Dong S; Zhang Y; Norman GL; Zhao Q; Liu L
    Scand J Gastroenterol; 2020 Jul; 55(7):806-813. PubMed ID: 32568566
    [No Abstract]   [Full Text] [Related]  

  • 10. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
    J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Validity of Anti-Proteinase 3 Antibodies in Patients with Inflammatory Bowel Disease: A Short Meta-Analysis.
    Andalucía C; Martínez-Prat L; Bentow C; Aure MA; Horn MP; Mahler M
    Diagnostics (Basel); 2023 Dec; 13(24):. PubMed ID: 38132266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease.
    Arias-Loste MT; Bonilla G; Moraleja I; Mahler M; Mieses MA; Castro B; Rivero M; Crespo J; López-Hoyos M
    Clin Rev Allergy Immunol; 2013 Aug; 45(1):109-16. PubMed ID: 23345025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNFα antibody versus non-anti-TNFα molecular agents for ulcerative colitis patients who failed initial anti-TNFα therapy.
    Kanayama K; Kato J; Shiratori W; Nagashima A; Ohta Y; Taida T; Saito K; Goto C; Takahashi S; Horio R; Kurosugi A; Ishikawa T; Kaneko T; Akizue N; Okimoto K; Matsumura T; Kato N
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1083-1089. PubMed ID: 35263810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of serum proteinase 3 antineutrophil cytoplasmic antibodies in children with ulcerative colitis.
    Mizuochi T; Arai K; Kudo T; Nambu R; Tajiri H; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Takaki Y; Konishi KI; Ishihara J; Obara H; Kakuma T; Kurei S; Yamashita Y; Mitsuyama K
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1538-1544. PubMed ID: 33047817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).
    Stinton LM; Bentow C; Mahler M; Norman GL; Eksteen B; Mason AL; Kaplan GG; Lindkvist B; Hirschfield GM; Milkiewicz P; Cheung A; Janssen HL; Fritzler MJ
    PLoS One; 2014; 9(11):e112877. PubMed ID: 25397578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
    McClure ME; Wason J; Gopaluni S; Tieu J; Smith RM; Jayne DR; Jones RB
    J Clin Rheumatol; 2019 Aug; 25(5):217-223. PubMed ID: 30896460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.